Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma

Urology

Volumn 77, Issue 4, 2011, Pages

  Filson, Christopher P ^a   Redman, Bruce G ^a   Dunn, Rodney L ^a   Miller, David C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SHORT COURSE THERAPY; TREATMENT INDICATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 79953877251     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.003     Document Type: Article

References (23)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417. (Pubitemid 30060482)
3. Gupta K, Miller J, Li J, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193-205.
4. Goodman V, Rock E, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13:1367-1373. (Pubitemid 46450424)
5. Kane R, Farrell A, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271-7278. (Pubitemid 46095398)
6. Motzer R, Hutson T, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
7. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
8. Motzer R, Hutson T, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
9. Steinbrook R. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med. 2008;359:1977-1981.
10. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-633.
11. Pollack A. As Pills Treat Cancer, Insurance Lags Behind. New York Times. Availabe from: www.nytimes.com/2009/04/15/business/15pill.html. Accessed July 3, 2010.
12. Health Research Data for the Real World: The MarketScan Databases. Available from: www.support.thomsonhealthcare.com/uploadedFiles/docs/ 2008HealthResearchDatafortheRealWorldThe%20MarketScanDatabases(1).pdf. Accessed July 3, 2010.
13. Gore M, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757-763.
14. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care. 2003;9:393-400. (Pubitemid 36617254)
15. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-131.
16. Strumburg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J Clin Oncol. 2008;26:3469.
17. Dougherty D, Conway PH. The "3T's" road map to transform US health care: the "how" of high-quality care. JAMA. 2008;299:2319-2321.
18. Dudek AZ, Zolniernek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol. 2009;115:61-67.
19. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol. 2008;54:1373-1378.
20. Di Lorenzo G, Carteni G, Autorino R, et al. Phase II Study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-4474.
21. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
22. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007;13:693s-696s.
23. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). Available from: www.clinicaltrials.gov/ct2/show/NCT00930033. Accessed July 3, 2010.